MEC
MCID: MCP006
MIFTS: 52

Mucoepidermoid Carcinoma (MEC)

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Mucoepidermoid Carcinoma

MalaCards integrated aliases for Mucoepidermoid Carcinoma:

Name: Mucoepidermoid Carcinoma 12 53 15 73
Carcinoma, Mucoepidermoid 44
Carcinoma Mucoepidermoid 55
Mec 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4531
MeSH 44 D018277
NCIt 50 C3772
SNOMED-CT 68 4079000
UMLS 73 C0206694

Summaries for Mucoepidermoid Carcinoma

NIH Rare Diseases : 53 Mucoepidermoid carcinoma is a type of cancer of the salivary glands.  Salivary gland cancer is diagnosed in 2-3 individuals per 100,000 people each year, and 30-35% of these are mucoepidermoid carcinomas.   Mucoepidermoid carcinoma develops when a cell randomly acquires changes (mutations) in genes that regulate how the cell divides such that it begins to grow quickly, forming a cluster of cells (a mass or lump).  The earliest signs of a mucoepidermoid carcinoma may include a lump in the face, neck, or mouth; numbness, weakness, or pain in part of the face; or difficulty swallowing.  Treatment often begins with surgery to remove the entire tumor.  In some cases, radiation therapy and/or chemotherapy may be used after surgery to ensure that no cancer cells remain in the body.

MalaCards based summary : Mucoepidermoid Carcinoma, also known as carcinoma, mucoepidermoid, is related to lacrimal gland mucoepidermoid carcinoma and cutaneous mucoepidermoid carcinoma. An important gene associated with Mucoepidermoid Carcinoma is LINC00473 (Long Intergenic Non-Protein Coding RNA 473), and among its related pathways/superpathways are CLEC7A (Dectin-1) signaling and O-linked glycosylation. The drugs Abstral and Arranon have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, thyroid and lung, and related phenotypes are digestive/alimentary and adipose tissue

Disease Ontology : 12 A salivary gland carcinoma that is characterized by squamous cells, mucus-secreting cells, and intermediate cells.

Wikipedia : 76 Mucoepidermoid carcinoma is the most common type of minor salivary gland malignancy in adults.... more...

Related Diseases for Mucoepidermoid Carcinoma

Diseases related to Mucoepidermoid Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 263)
# Related Disease Score Top Affiliating Genes
1 lacrimal gland mucoepidermoid carcinoma 34.0 CRTC1 MAML2
2 cutaneous mucoepidermoid carcinoma 33.9 CRTC1 KRT7 MAML2
3 breast mucoepidermoid carcinoma 33.7 CRTC1 MAML2 MUC1 MUC5AC
4 bile duct mucoepidermoid carcinoma 33.3 KRT7 MUC1 MUC2 MUC4 MUC5AC
5 mucoepidermoid thyroid carcinoma 32.1 CALCA TG
6 pleomorphic adenoma 30.9 ERBB2 KRT14 MUC1 TP63
7 pleomorphic adenoma carcinoma 30.8 ERBB2 MAML2
8 adenocarcinoma 30.7 EGFR ERBB2 MUC1 MUC4
9 warthin tumor 30.6 CRTC1 CRTC3 KRT7 MAML2
10 adenosquamous carcinoma 30.5 EGFR KRT7 MUC1 MUC4 TP63
11 squamous cell carcinoma 30.4 EGFR ERBB2 MKI67 MUC1 TP63
12 adenoid cystic carcinoma 30.3 ERBB2 KRT14 KRT7 MKI67 MUC1 TP63
13 papillary carcinoma 30.2 CALCA ERBB2 KRT7 MUC1 TG
14 oral cancer 30.2 EGFR KRT13 PCNA
15 hidradenoma 30.1 KRT7 MAML2 MUC1
16 carcinosarcoma 30.0 ERBB2 KRT7 MUC1
17 mucinous adenocarcinoma 29.9 EGFR KRT7 MUC1 MUC2
18 basaloid squamous cell carcinoma 29.9 EGFR KRT13 KRT14 KRT7
19 cystadenoma 29.7 CHGA KRT7 MUC1 MUC2 MUC4
20 papilloma 29.7 KRT13 KRT14 KRT7 PCNA TP63
21 renal cell carcinoma, nonpapillary 29.3 EGFR KRT7 LINC00473 MUC1
22 gastric adenocarcinoma 29.3 CHGA EGFR ERBB2 KRT7 MUC1 MUC2
23 lung cancer 29.1 AREG CHGA EGFR ERBB2 KRT7 LINC00473
24 sclerosing mucoepidermoid carcinoma with eosinophilia 12.5
25 thymus mucoepidermoid carcinoma 12.4
26 lung mucoepidermoid carcinoma 12.3
27 laryngeal mucoepidermoid carcinoma 12.3
28 bronchus mucoepidermoid carcinoma 12.1
29 trachea mucoepidermoid carcinoma 12.1
30 mucoepidermoid esophageal carcinoma 11.6
31 paranasal sinus cancer 11.4
32 ceruminous adenocarcinoma 11.2
33 adenoma 10.5
34 clear cell hidradenoma 10.4 CRTC1 MAML2
35 endosalpingiosis 10.3 KRT7 MUC1
36 nodular hidradenoma 10.3 KRT7 MUC1
37 parachordoma 10.3 KRT7 MUC1
38 secretory meningioma 10.3 KRT7 MUC1
39 middle ear adenoma 10.3 KRT7 MUC1
40 cribriform carcinoma 10.3 KRT7 TP63
41 ovarian germ cell cancer 10.3 KRT7 TG
42 breast intraductal proliferative lesion 10.3 EGFR ERBB2
43 leukemia, acute lymphoblastic 10.3
44 leukemia 10.3
45 lymphocytic leukemia 10.3
46 large cell acanthoma 10.3 KRT14 KRT7
47 apocrine sweat gland neoplasm 10.3 KRT14 KRT7
48 benign breast phyllodes tumor 10.3 MKI67 TP63
49 breast scirrhous carcinoma 10.2 EGFR ERBB2 MUC1
50 breast cystic hypersecretory carcinoma 10.2 ERBB2 TG

Graphical network of the top 20 diseases related to Mucoepidermoid Carcinoma:



Diseases related to Mucoepidermoid Carcinoma

Symptoms & Phenotypes for Mucoepidermoid Carcinoma

MGI Mouse Phenotypes related to Mucoepidermoid Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.76 AREG EGFR ERBB2 KRT14 MUC2 MUC5AC
2 adipose tissue MP:0005375 9.73 CRTC1 CRTC3 EGFR KRT14 PCNA TG
3 endocrine/exocrine gland MP:0005379 9.65 AREG CHGA CRTC1 EGFR ERBB2 KRT14
4 homeostasis/metabolism MP:0005376 9.4 AREG CHGA CRTC1 CRTC3 EGFR ERBB2

Drugs & Therapeutics for Mucoepidermoid Carcinoma

FDA approved drugs:

(show all 41)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Abstral 18 FENTANYL (citrate) ProStrakan January 2011
2
Arranon 18 49 NELARABINE GlaxoSmithKline October 2005
3
Arzerra 18 49 OFATUMUMAB GlaxoSmithKline October 2009
4
Bexxar 18 49 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa June 2003
5
Ellence 18 49 EPIRUBICIN HYDROCHLORIDE Pharmacia & Upjohn September 1999
6
Erwinaze 18 49 asparaginase Erwinia chrysanthemi Eusa Pharma November of 2011
7
Faslodex 18 49 FULVESTRANT AstraZeneca April 2002
8
Gazyva 18 49 OBINUTUZUMAB Genentech October of 2013
9
Halaven 18 49 ERIBULIN MESYLATE Eisai November 2010
10
Intron A 18 49 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
11
Iressa 18 49 GEFITINIB AstraZeneca May 2003
12
Istodax 18 49 ROMIDEPSIN Gloucester Pharmaceuticals November 2009
13
Onsolis 18 FENTANYL CITRATE BioDelivery Sciences July 2009
14
Picato gel 18 INGENOL MEBUTATE LEO Pharma January 2012
15
Provenge 18 49 sipuleucel-T Dendreon May 2010
16
Subsys 18 FENTANYL Insys Therapeutics January of 2012
17
Sylatron 18 49 PEGINTERFERON ALFA-2B Merck April 2011
18
Tarceva 18 49 ERLOTINIB HYDROCHLORIDE Genentech, OSI Pharmaceuticals November, 2004
19
Treanda 18 49 BENDAMUSTINE HYDROCHLORIDE Cephalon October 2008
20
Trisenox 18 49 ARSENIC TRIOXIDE Cell Therapeutics September 2000
21
Valchlor 18 MECHLORETHAMINE HYDROCHLORIDE Ceptaris Therapeutics August 2013
22
Valstar 18 VALRUBICIN Anthra Pharmaceuticals October 1998
23
Velcade 18 49 BORTEZOMIB Millennium Pharmaceuticals May 2003
24
Yervoy 18 49 IPILIMUMAB Bristol-Myers Squibb March 2011
25
Zometa 18 49 ZOLEDRONIC ACID Novartis August 2001/ February 2002
26
Anoro Ellipta 18 UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE GlaxoSmithKline December of 2013
27
Arnuity Ellipta 18 FLUTICASONE FUROATE GlaxoSmithKline August 2014
28
Avelox I.V. 18 MOXIFLOXACIN HYDROCHLORIDE Bayer November 2001
29
Cafcit Injection 18 CAFFEINE CITRATE Roxane Laboratories September 1999
30
Daliresp 18 ROFLUMILAST Forest Pharmaceuticals February 2011
31
Dymista 18 AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE Meda Pharmaceuticals Inc May 2012
32
Esbriet 18 PIRFENIDONE InterMune October 2014
33
Grastek 18 Timothy Grass Pollen Allergen Extract Merck April 2014
34
Incruse Ellipta 18 UMECLIDINIUM BROMIDE GlaxoSmithKline May 2014
35
Nucala 18 MEPOLIZUMAB GlaxoSmithKline November 2015
36
Ofev 18 NINTEDANIB ESYLATE Boehringer Ingelheim October 2014
37
Qnasl 18 BECLOMETHASONE DIPROPIONATE Teva Pharmaceutical March 2012
38
Ragwitek 18 Merck April 2014
39
Rhinocort Aqua Nasal Spray 18 BUDESONIDE AstraZeneca October 1999
40
Tequin 18 Bristol-Myers Squibb December, 1999
41
Tri-Nasal Spray 18 Muro Pharmaceutical February 2000

Drugs for Mucoepidermoid Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 153)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
2
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
3
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
4
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
5
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
6
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
7
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
8
Docetaxel Approved, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124
9 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
10 Cola Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Liver Extracts Phase 3,Phase 2,Phase 1,Early Phase 1
12 Anti-Infective Agents Phase 2, Phase 3,Phase 1
13 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
14 Antimitotic Agents Phase 3,Phase 1,Phase 2
15 Neurotransmitter Agents Phase 3,Not Applicable
16 Histamine Antagonists Phase 3
17 Psychotropic Drugs Phase 3
18 Antidepressive Agents Phase 3
19
Histamine Phosphate Phase 3 51-74-1 65513
20 Antidepressive Agents, Tricyclic Phase 3
21 Central Nervous System Depressants Phase 3
22 Adjuvants, Anesthesia Phase 3
23 Anesthetics, Intravenous Phase 3
24 Analgesics, Opioid Phase 3
25 Peripheral Nervous System Agents Phase 3,Not Applicable
26 Anesthetics, General Phase 3
27 Analgesics Phase 3
28 Narcotics Phase 3
29 Anesthetics Phase 3
30 Steroid Synthesis Inhibitors Phase 2, Phase 3
31 Hormone Antagonists Phase 2, Phase 3
32 Antifungal Agents Phase 2, Phase 3,Phase 1
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
34 Hormones Phase 2, Phase 3,Phase 1
35 Cytochrome P-450 CYP2C19 Inhibitors Phase 2, Phase 3
36 Cytochrome P-450 CYP2C9 Inhibitors Phase 2, Phase 3
37 Cholinergic Agents Phase 3,Not Applicable
38 Autonomic Agents Phase 3,Not Applicable
39 Muscarinic Agonists Phase 3
40 Contraceptive Agents Phase 3
41
Megestrol Phase 3 3562-63-8 19090 3080587
42 Contraceptives, Oral Phase 3
43 Antineoplastic Agents, Hormonal Phase 3
44 Central Nervous System Stimulants Phase 3,Not Applicable
45 Appetite Stimulants Phase 3
46
Paclitaxel Approved, Vet_approved Phase 1, Phase 2,Phase 2 33069-62-4 36314
47
Cisplatin Approved Phase 1, Phase 2,Phase 2 15663-27-1 2767 441203 84093
48
Amifostine Approved, Investigational Phase 1, Phase 2,Phase 2 20537-88-6 2141
49
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
50
Indinavir Approved Phase 2 150378-17-9 5362440

Interventional clinical trials:

(show top 50) (show all 79)
# Name Status NCT ID Phase Drugs
1 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
2 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
3 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
4 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
5 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
6 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
7 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
8 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
9 Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
10 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
11 Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery Completed NCT00003744 Phase 2 gemcitabine
12 Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer Completed NCT00002632 Phase 2 paclitaxel
13 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
14 Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
15 Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers Completed NCT00095563 Phase 2 lapatinib ditosylate
16 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2 docetaxel
17 High-dose ICE With Amifostine Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
18 Docetaxel in Treating Patients With Solid Tumors Completed NCT00003565 Phase 2 docetaxel
19 Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer Completed NCT00448552 Phase 2 capecitabine;oxaliplatin
20 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth Cancer Completed NCT00004901 Phase 1, Phase 2 ethynyluracil;fluorouracil;hydroxyurea
21 Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor Completed NCT00021047 Phase 1, Phase 2 capecitabine;carboplatin;epirubicin hydrochloride
22 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
23 Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer Completed NCT00004163 Phase 2 Trastuzumab
24 Cisplatin or Carboplatin Combined With Gemcitabine in Treating Patients With Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor Completed NCT00079079 Phase 2 carboplatin;cisplatin;gemcitabine hydrochloride
25 Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer Completed NCT00509665 Phase 2 doxorubicin hydrochloride;gemcitabine hydrochloride
26 Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer Completed NCT00021333 Phase 2 cisplatin;paclitaxel
27 Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene Recruiting NCT03602079 Phase 1, Phase 2 A166
28 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery Recruiting NCT01220583 Phase 2 cisplatin
29 Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy Active, not recruiting NCT02123511 Phase 2 acetylcysteine
30 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Active, not recruiting NCT01806675 Phase 1, Phase 2 fludeoxyglucose F 18;2-fluoropropionyl-labeled pegylated dimeric RGD peptide
31 Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer Terminated NCT00126607 Phase 2
32 Title XELOX FOR SALIVARY GLAND CANCERS Terminated NCT00101075 Phase 2 Capecitabine;Oxaliplatin
33 Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer Completed NCT00470496 Phase 1 HPPH;photodynamic therapy
34 Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors Completed NCT00089362 Phase 1 alvespimycin hydrochloride
35 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
36 Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00023959 Phase 1 hydroxyurea;fluorouracil
37 Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer Completed NCT01637194 Phase 1 everolimus
38 Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
39 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
40 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
41 Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors Completed NCT01172028 Phase 1 Taxotere (Docetaxel);Alimta (Pemetrexed)
42 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
43 Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors Completed NCT00006036 Phase 1 cisplatin;lurtotecan liposome
44 Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function Completed NCT00002901 Phase 1 docetaxel
45 Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer Completed NCT00045006 Phase 1 vorinostat
46 Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer Completed NCT00019110 Phase 1
47 Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors Completed NCT00010023 Phase 1 capecitabine;cisplatin
48 Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer Completed NCT00004065 Phase 1 tanespimycin
49 NGR-TNF in Treating Patients With Advanced Solid Tumors Completed NCT00098943 Phase 1
50 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1 docetaxel;thalidomide

Search NIH Clinical Center for Mucoepidermoid Carcinoma

Cochrane evidence based reviews: carcinoma, mucoepidermoid

Genetic Tests for Mucoepidermoid Carcinoma

Anatomical Context for Mucoepidermoid Carcinoma

MalaCards organs/tissues related to Mucoepidermoid Carcinoma:

41
Salivary Gland, Thyroid, Lung, Liver, Breast, Trachea, Thymus

Publications for Mucoepidermoid Carcinoma

Articles related to Mucoepidermoid Carcinoma:

(show top 50) (show all 1021)
# Title Authors Year
1
Mucoepidermoid Carcinoma: A 23-Year Experience with Emphasis on Low-Grade Tumors with Close/Positive Margins. ( 29313462 )
2018
2
Mucoepidermoid Carcinoma Mimicking a Lesion of Endodontic Origin. ( 29935872 )
2018
3
Clinicopathological characteristics and molecular analysis of primary pulmonary mucoepidermoid carcinoma: Case report and literature review. ( 29388384 )
2018
4
Mucoepidermoid Carcinoma of Arising from a Bronchogenic Cyst of the Diaphragm. ( 29367500 )
2018
5
CRTC1-MAML2 fusion-induced lncRNA LINC00473 expression maintains the growth and survival of human mucoepidermoid carcinoma cells. ( 29353885 )
2018
6
Low grade parotid mucoepidermoid carcinoma with tumour associated lymphoid proliferation ("Warthin-like") and CRTC1-MAML2 fusion transcript: Definitive diagnosis with molecular investigation only. ( 29571603 )
2018
7
Mucoepidermoid carcinoma of the parotid gland: A National Cancer Database study. ( 29559174 )
2018
8
An Extracranial Metastasis of Glioblastoma Mimicking Mucoepidermoid Carcinoma. ( 29852299 )
2018
9
Parotid Mucoepidermoid Carcinoma Mimicking a Large Mucocele. ( 29461375 )
2018
10
Apoptosis induced by methanol extract of PotentillaA discolor in human mucoepidermoid carcinoma cells through STAT3/PUMA signaling axis. ( 29363716 )
2018
11
Pulmonary mucoepidermoid carcinoma: diagnosis and treatment. ( 29338644 )
2018
12
Central mucoepidermoid carcinoma arising from glandular odontogenic cyst confirmed by analysis of MAML2 rearrangement: A case report. ( 29131467 )
2018
13
Central mucoepidermoid carcinoma: An up-to-date analysis of 147 cases and review of prognostic factors. ( 29198377 )
2018
14
You cannot miss it: Pancreatic mucoepidermoid carcinoma: A case report and literature review. ( 29538223 )
2018
15
Surgery combined with radio-chemotherapy for esophageal mucoepidermoid carcinoma: A case report. ( 29901650 )
2018
16
Sclerosing mucoepidermoid carcinoma with eosinophilia: Cytologic characterization of a rare distinct entity in the thyroid. ( 29479842 )
2018
17
Unique application of awake tracheoscopy and endobronchial ultrasound in the management of tracheal mucoepidermoid carcinoma. ( 29575399 )
2018
18
Mucoepidermoid carcinoma of the trachea. ( 29675367 )
2018
19
Mucoepidermoid carcinoma mimicking a mucocele (ranula) in the floor of the mouth. ( 29231036 )
2018
20
Has the management of pediatric mucoepidermoid carcinoma of the parotid gland changed? ( 29658113 )
2018
21
Sclerosing mucoepidermoid carcinoma with eosinophilia of thyroid gland: Not so indolent a neoplasm? ( 29676367 )
2018
22
Expression of vimentin and CD44 in mucoepidermoid carcinoma: A role in tumor growth. ( 29900918 )
2018
23
A Comparative Study of Primary Adenoid Cystic and Mucoepidermoid Carcinoma of Lung. ( 29868475 )
2018
24
Uncommon Types of Lung Carcinoma With Mixed Histology: Sarcomatoid Carcinoma, Adenosquamous Carcinoma, and Mucoepidermoid Carcinoma. ( 30040455 )
2018
25
"Pancreatic Mucoepidermoid Carcinoma" Is not a Pancreatic Counterpart of CRTC1/3-MAML2 Fusion Gene-related Mucoepidermoid Carcinoma of the Salivary Gland, and May More Appropriately be Termed Pancreatic Adenosquamous Carcinoma With Mucoepidermoid Carcinoma-like Features. ( 30138216 )
2018
26
Dedifferentiation of oncocytic epithelial-myoepithelial carcinoma to mucoepidermoid carcinoma in parotid gland: A rare case report. ( 30303150 )
2018
27
Adjuvant conundrum in central mucoepidermoid carcinoma of the mandible: case presentation and literature review. ( 30196261 )
2018
28
Mucoepidermoid Carcinoma in Warthin Tumor of the Parotis in Childhood: A Case Report and Review of the Literature. ( 30198962 )
2018
29
Mutational screen of a panel of tumor genes in a case report of mucoepidermoid carcinoma of the breast from Jordan. ( 30251446 )
2018
30
Inhibition of Protein Phosphatase 2A Sensitizes Mucoepidermoid Carcinoma to Chemotherapy via the PI3K-AKT Pathway in Response to Insulin Stimulus. ( 30282066 )
2018
31
High-grade Mucoepidermoid Carcinoma of the Lacrimal Gland. ( 30311467 )
2018
32
Mucoepidermoid carcinoma of the anal canal: A case report and review of the literature. ( 30345043 )
2018
33
Radiation treatment to a postresection primary mucoepidermoid carcinoma (MEC) of the conjunctiva with positive margins at the Tenon's fascia-A case study. ( 30366619 )
2018
34
CRTC1-MAML2 fusion in mucoepidermoid carcinoma of the breast. ( 30380176 )
2018
35
HIF-1α, NOTCH1, ADAM12, and HB-EGF are overexpressed in mucoepidermoid carcinoma. ( 30415904 )
2018
36
Screening and bioinformatics analysis of mRNA, long non-coding RNA and circular RNA expression profiles in mucoepidermoid carcinoma of salivary gland. ( 30471855 )
2018
37
Postoperative radiotherapy for T1/2N0M0 mucoepidermoid carcinoma positive for CRTC1/3-MAML2 fusions. ( 30475407 )
2018
38
A mismatch of tumor grade and biologic behaviour in a rare case of Sclerosing Mucoepidermoid Carcinoma of Parotid - with review of literature. ( 30476387 )
2018
39
Hydrogen Sulfide-Synthesizing Enzymes Are Altered in a Case of Oral Cavity Mucoepidermoid Carcinoma. ( 30483098 )
2018
40
Non-contrast computed tomography and magnetic resonance imaging features of mucoepidermoid carcinoma in the salivary glands. ( 30484090 )
2018
41
Mucoepidermoid carcinoma of the minor salivary gland: Presenting as ranula. ( 30488866 )
2018
42
Ablation of cancer stem cells by therapeutic inhibition of the MDM2-p53 interaction in mucoepidermoid carcinoma. ( 30498096 )
2018
43
Interfering with bromodomain epigenome readers as therapeutic option in mucoepidermoid carcinoma. ( 30539410 )
2018
44
A Rare Case of Pulmonary Mucoepidermoid Carcinoma in an 81-Year-Old Male. ( 30555150 )
2018
45
Bronchial Mucoepidermoid Carcinoma With the Classic MAML2 Gene Rearrangement in a 2-year-old Boy. ( 28492094 )
2018
46
Multilocular Thymic Cyst With Mucinous Differentiation: A Mimicker of Thymic Mucoepidermoid Carcinoma. ( 28508687 )
2018
47
Prognostic factors in head and neck mucoepidermoid carcinoma: experience at a single institution based on 64 consecutive patients over a 28-year period. ( 28969884 )
2018
48
P14 methylation: an epigenetic signature of salivary gland mucoepidermoid carcinoma in the Serbian population. ( 29079368 )
2018
49
miRNA expression profile of mucoepidermoid carcinoma. ( 29095552 )
2018
50
Thyroid sclerosing mucoepidermoid carcinoma with eosinophilia distinct from the salivary type. ( 29415898 )
2018

Variations for Mucoepidermoid Carcinoma

Cosmic variations for Mucoepidermoid Carcinoma:

9 (show top 50) (show all 125)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6915468 TGFBR1 salivary gland,minor,carcinoma,mucoepidermoid carcinoma c.324A>C p.K108N 9:99129081-99129081 16
2 COSM44850 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.494A>T p.Q165L 17:7675118-7675118 15
3 COSM46283 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.569C>A p.P190H 17:7674962-7674962 15
4 COSM43680 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.523C>T p.R175C 17:7675089-7675089 15
5 COSM44119 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.483C>T p.A161A 17:7675129-7675129 15
6 COSM43797 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.550G>C p.D184H 17:7675062-7675062 15
7 COSM46282 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.501G>C p.Q167H 17:7675111-7675111 15
8 COSM44853 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.661G>A p.E221K 17:7674870-7674870 15
9 COSM1389051 SMAD4 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.993G>A p.M331I 18:51065460-51065460 15
10 COSM5995773 SDHA salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.724G>A p.G242R 5:228287-228287 15
11 COSM5069 PTEN salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.760A>G p.K254E 10:87957978-87957978 15
12 COSM546 KRAS salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.175G>A p.A59T 12:25227349-25227349 15
13 COSM483 HRAS salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.35G>T p.G12V 11:534288-534288 15
14 COSM491 HRAS salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.39T>A p.G13G 11:534284-534284 15
15 COSM489 HRAS salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.38G>T p.G13V 11:534285-534285 15
16 COSM484 HRAS salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.35G>A p.G12D 11:534288-534288 15
17 COSM3596039 BAP1 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.376-1G>A p.? 3:52407461-52407461 15
18 COSM120918 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.38G>T p.G13V 11:534285-534285 15
19 COSM10648 TP53 salivary gland,minor,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 12
20 COSM69404 TP53 salivary gland,minor,carcinoma,NS c.994-1G>A p.? 17:7670716-7670716 12
21 COSM11552 TP53 salivary gland,minor,carcinoma,NS c.775G>T p.D259Y 17:7674188-7674188 12
22 COSM6935085 TENT5C salivary gland,minor,carcinoma,NS c.833T>A p.F278Y 1:117623701-117623701 12
23 COSM4728291 SMARCA4 salivary gland,minor,carcinoma,NS c.2372C>T p.A791V 19:11013046-11013046 12
24 COSM6915408 SF3B1 salivary gland,minor,carcinoma,NS c.3254C>T p.A1085V 2:197397997-197397997 12
25 COSM6910358 SETD2 salivary gland,minor,carcinoma,NS c.4870C>T p.Q1624* 3:47057405-47057405 12
26 COSM41699 RUNX1 salivary gland,minor,carcinoma,NS c.958C>T p.R320* 21:34799310-34799310 12
27 COSM6928612 RPTOR salivary gland,minor,carcinoma,NS c.734C>T p.A245V 17:80754089-80754089 12
28 COSM6910364 RARA salivary gland,minor,carcinoma,NS c.691C>G p.L231V 17:40352391-40352391 12
29 COSM13023 PTPN11 salivary gland,minor,carcinoma,NS c.1505C>T p.S502L 12:112489081-112489081 12
30 COSM6935088 PIK3CG salivary gland,minor,carcinoma,NS c.2951C>A p.P984Q 7:106886213-106886213 12
31 COSM757 PIK3CA salivary gland,minor,carcinoma,NS c.1258T>C p.C420R 3:179210192-179210192 12
32 COSM1420934 PIK3CA salivary gland,minor,carcinoma,NS c.3012G>A p.M1004I 3:179234169-179234169 12
33 COSM763 PIK3CA salivary gland,minor,carcinoma,NS c.1633G>A p.E545K 3:179218303-179218303 12
34 COSM6913851 PBRM1 salivary gland,minor,carcinoma,NS c.2284G>C p.D762H 3:52609596-52609596 12
35 COSM6909937 NOTCH1 salivary gland,minor,carcinoma,NS c.973A>G p.N325D 9:136518717-136518717 12
36 COSM6916910 NOTCH1 salivary gland,minor,carcinoma,NS c.403+1G>C p.? 9:136523716-136523716 12
37 COSM13044 NOTCH1 salivary gland,minor,carcinoma,NS c.5101G>C p.A1701P 9:136503248-136503248 12
38 COSM3929943 NOTCH1 salivary gland,minor,carcinoma,NS c.1367G>A p.C456Y 9:136517826-136517826 12
39 COSM13081 NOTCH1 salivary gland,minor,carcinoma,NS c.7400C>A p.S2467* 9:136496339-136496339 12
40 COSM6842736 NF1 salivary gland,minor,carcinoma,NS c.3449C>G p.S1150* 17:31232834-31232834 12
41 COSM6910361 MAX salivary gland,minor,carcinoma,NS c.295+1G>A p.? 14:65077912-65077912 12
42 COSM6927303 MAP2K4 salivary gland,minor,carcinoma,NS c.551C>G p.S184W 17:12107827-12107827 12
43 COSM4042348 KMT2D salivary gland,minor,carcinoma,NS c.12640C>T p.R4214* 12:49031255-49031255 12
44 COSM51381 KIT salivary gland,face,carcinoma,NS c.2386A>G p.R796G 4:54733094-54733094 12
45 COSM6925975 HGF salivary gland,minor,carcinoma,NS c.1444+1G>A p.? 7:81711480-81711480 12
46 COSM6910360 FGFR3 salivary gland,minor,carcinoma,NS c.1682G>C p.G561A 4:1805786-1805786 12
47 COSM6916439 EZH2 salivary gland,minor,carcinoma,NS c.938G>A p.R313Q 7:148819657-148819657 12
48 COSM6935087 ETV1 salivary gland,minor,carcinoma,NS c.971G>T p.R324L 7:13906569-13906569 12
49 COSM1242240 ERBB3 salivary gland,minor,carcinoma,NS c.695C>T p.A232V 12:56087876-56087876 12
50 COSM6913854 EP300 salivary gland,minor,carcinoma,NS c.3110C>T p.S1037L 22:41152318-41152318 12

Expression for Mucoepidermoid Carcinoma

Search GEO for disease gene expression data for Mucoepidermoid Carcinoma.

Pathways for Mucoepidermoid Carcinoma

GO Terms for Mucoepidermoid Carcinoma

Cellular components related to Mucoepidermoid Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.8 AREG CALCA CRTC1 CRTC3 EGFR ERBB2
2 keratin filament GO:0045095 9.33 KRT13 KRT14 KRT7
3 Golgi lumen GO:0005796 8.92 MUC1 MUC2 MUC4 MUC5AC

Biological processes related to Mucoepidermoid Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to estradiol GO:0032355 9.63 AREG EGFR PCNA
2 cell proliferation GO:0008283 9.63 AREG EGFR ERBB2 MKI67 PCNA TP63
3 protein homotetramerization GO:0051289 9.54 CRTC1 CRTC3 TP63
4 epithelial cell differentiation GO:0030855 9.5 KRT14 PCNA TP63
5 negative regulation of cAMP-mediated signaling GO:0043951 9.43 CRTC3 LINC00473
6 maintenance of gastrointestinal epithelium GO:0030277 9.4 MUC2 MUC4
7 negative regulation of ERBB signaling pathway GO:1901185 9.26 EGFR ERBB2
8 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.26 MUC1 MUC2 MUC4 MUC5AC
9 O-glycan processing GO:0016266 8.92 MUC1 MUC2 MUC4 MUC5AC

Molecular functions related to Mucoepidermoid Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cAMP response element binding protein binding GO:0008140 8.62 CRTC1 CRTC3

Sources for Mucoepidermoid Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....